A.M. Pappas & Associates of Research Triangle Park is one of two firms making a Series A extension round of $3.5 million in Signase, a chemistry-based company focused on drug discovery.

Joining Pappas is Tripos Inc. of St. Louis, a software and discovery chemistry research firm. Both firms also had provided seed funding, according to Signase. BioCapital of Montreal also participated in the seed round.

Signase is focused on therapeutics and inhibitors designed to have applications for cancer, osteoporosis, the immune system and central nervous system disorders.